Novel Drug Beats Avonex for MS Efficacy; Safety Still a Worry

BOSTON (MedPage Today) -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head again.
Source: MedPage Today Meeting Coverage - Category: Journals (General) Source Type: news